Report overview
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
This report aims to provide a comprehensive presentation of the global market for Liposome Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Drug Delivery. This report contains market size and forecasts of Liposome Drug Delivery in global, including the following market information:
Global Liposome Drug Delivery Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Liposome Drug Delivery Market Sales, 2018-2023, 2024-2029, (K Vial)
Global top five Liposome Drug Delivery companies in 2022 (%)
The global Liposome Drug Delivery market was valued at US$ 3842.1 million in 2022 and is projected to reach US$ 8627 million by 2029, at a CAGR of 12.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
We surveyed the Liposome Drug Delivery manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Liposome Drug Delivery Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Vial)
Global Liposome Drug Delivery Market Segment Percentages, by Type, 2022 (%)
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Global Liposome Drug Delivery Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Vial)
Global Liposome Drug Delivery Market Segment Percentages, by Application, 2022 (%)
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
Global Liposome Drug Delivery Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Vial)
Global Liposome Drug Delivery Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Liposome Drug Delivery revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Liposome Drug Delivery revenues share in global market, 2022 (%)
Key companies Liposome Drug Delivery sales in global market, 2018-2023 (Estimated), (K Vial)
Key companies Liposome Drug Delivery sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liposome Drug Delivery, market overview.
Chapter 2: Global Liposome Drug Delivery market size in revenue and volume.
Chapter 3: Detailed analysis of Liposome Drug Delivery manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liposome Drug Delivery in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Liposome Drug Delivery capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
